Benzinga’s Top Pre-Market NASDAQ Gainers (RMBS, CYTX, NVAX, TLAB)
Rambus Inc (NASDAQ: RMBS) rose 10.82% to $21.71 in the pre-market session. RMBS won its fight against Nvidia (NASDAQ: NVDA) and other companies yesterday after the trade panel agreed that RMBS’ patents were getting infringed.
Cytori Therapeutics Inc (NASDAQ: CYTX) added 7.28% to $5.01 in pre-market trading. In Europe, Cytori has gained the approval of its stem cell device used for breast reconstruction and repair of defects in soft tissue.
Novavax Inc (NASDAQ: NVAX) moved up 7.14% to $2.40 in pre-market trading. NVAX has been issued the key US Patent for Influenza Virus-like Particle (VLP) vaccines.
Tellabs Inc (NASDAQ: TLAB) gained 5.91% to $8.25 in the pre-market session. TLAB has reported better-than-expected Q2 results and issued strong Q3 revenue projections.
Read more from Benzinga's Company news.
